51 |
Merck KGaA et al v. Aurobindo Pharma USA, Inc. et al |
1:23-cv-00039 |
D.Del. |
|
|
|
|
52 |
Merck KGaA et al v. Aurobindo Pharma USA, Inc. et al |
1:23-cv-00039 |
D.Del. |
|
|
|
|
53 |
Merck KGaA et al v. Hopewell Pharma Ventures, Inc., et al. |
1:22-cv-01365 |
D.Del. |
|
|
|
|
54 |
Merck KGaA et al v. Hopewell Pharma Ventures, Inc., et al. |
1:22-cv-01365 |
D.Del. |
|
|
|
|
55 |
Merck KGaA et al v. Hopewell Pharma Ventures, Inc., et al. |
1:22-cv-01365 |
D.Del. |
|
|
|
|
56 |
MERCK, SHARP & DOHME CORP. et al v. AUROBINDO PHARMA LTD. et al |
1:13-cv-05442 |
D.N.J. |
|
|
|
|
57 |
MERCK, SHARP & DOHME CORP. et al v. AUROBINDO PHARMA LTD. et al |
1:13-cv-05442 |
D.N.J. |
|
|
|
|
58 |
MERCK, SHARP & DOHME CORP. et al v. AUROBINDO PHARMA LTD. et al |
1:13-cv-05442 |
D.N.J. |
|
|
|
|
59 |
Mylan Institutional LLC et al v. Aurobindo Pharma Ltd et al |
2:16-cv-00491 |
E.D.Tex. |
|
|
|
|
60 |
Mylan Institutional LLC et al v. Aurobindo Pharma Ltd et al |
2:16-cv-00491 |
E.D.Tex. |
|
|
|
|
61 |
NOVARTIS PHARMACEUTICALS CORPORATION v. AUROBINDO PHARMA LIMITED et al |
3:10-cv-06283 |
D.N.J. |
|
|
|
|
62 |
Pfizer Inc. et al v. Aurobindo Pharma Limited |
1:23-cv-00923 |
D.Del. |
|
|
|
|
63 |
Pfizer Inc. et al v. Aurobindo Pharma Limited |
1:23-cv-00923 |
D.Del. |
|
|
|
|
64 |
Pfizer Inc. et al v. Aurobindo Pharma Limited |
1:23-cv-00923 |
D.Del. |
|
|
|
|
65 |
Pfizer Inc. et al v. Aurobindo Pharma Limited |
1:23-cv-00923 |
D.Del. |
|
|
|
|
66 |
Pfizer Inc. et al v. Aurobindo Pharma Limited |
1:23-cv-00923 |
D.Del. |
|
|
|
|
67 |
Sanofi-Aventis U.S. LLC et al v. Aurobindo Pharma USA, Inc., et al. |
1:16-cv-01299 |
D.Del. |
|
- 8 Product company
- 12 IP subsidiary of product company
|
|
|
68 |
Sanofi-Aventis U.S. LLC et al v. Aurobindo Pharma USA, Inc., et al. |
1:16-cv-01299 |
D.Del. |
|
- 8 Product company
- 12 IP subsidiary of product company
|
|
|
69 |
Sanofi-Aventis U.S. LLC et al v. Aurobindo Pharma USA, Inc., et al. |
1:16-cv-01299 |
D.Del. |
|
- 8 Product company
- 12 IP subsidiary of product company
|
|
|
70 |
Sanofi-Aventis U.S. LLC et al v. Aurobindo Pharma USA, Inc., et al. |
1:16-cv-01299 |
D.Del. |
|
- 8 Product company
- 12 IP subsidiary of product company
|
|
|
71 |
TAKEDA PHARMACEUTICAL COMPANY LIMITED et al v. AUROBINDO PHARMA LIMITED et al |
2:10-cv-00319 |
D.N.J. |
|
|
|
|
72 |
TAKEDA PHARMACEUTICAL COMPANY LIMITED et al v. AUROBINDO PHARMA LIMITED et al |
2:10-cv-00319 |
D.N.J. |
|
|
|
|
73 |
Takeda Pharmaceutical Company Limited et al v. Aurobindo Pharma Limited et al |
1:10-cv-01339 |
S.D.N.Y. |
|
|
|
|
74 |
Takeda Pharmaceutical Company Limited et al v. Aurobindo Pharma Limited et al |
1:10-cv-01339 |
S.D.N.Y. |
|
|
|
|
75 |
Takeda Pharmaceutical Company Limited et al v. Aurobindo Pharma Limited et al |
1:10-cv-01339 |
S.D.N.Y. |
|
|
|
|
76 |
Teva Pharmaceuticals International GmbH et al v. Aurobindo Pharma, Ltd. et al |
1:20-cv-00632 |
D.Del. |
|
|
|
|
77 |
Teva Pharmaceuticals International GmbH et al v. Aurobindo Pharma, Ltd. et al |
1:20-cv-00632 |
D.Del. |
|
|
|
|
78 |
Teva Pharmaceuticals International GmbH et al v. Aurobindo Pharma, Ltd. et al |
1:20-cv-00632 |
D.Del. |
|
|
|
|
79 |
THE MEDICINES COMPANY v. AUROBINDO PHARMA LIMITED et al |
3:14-cv-02367 |
D.N.J. |
|
|
|
|
80 |
THERAVANCE BIOPHARMA R&D IP, LLC et al v. EUGIA PHARMA SPECIALTIES LTD. et al |
1:23-cv-00926 |
D.N.J. |
|
|
|
|
81 |
THERAVANCE BIOPHARMA R&D IP, LLC et al v. EUGIA PHARMA SPECIALTIES LTD. et al |
1:23-cv-00926 |
D.N.J. |
|
|
|
|
82 |
THERAVANCE BIOPHARMA R&D IP, LLC et al v. EUGIA PHARMA SPECIALTIES LTD. et al |
1:23-cv-00926 |
D.N.J. |
|
|
|
|
83 |
THERAVANCE BIOPHARMA R&D IP, LLC et al v. EUGIA PHARMA SPECIALTIES LTD. et al |
1:23-cv-00926 |
D.N.J. |
|
|
|
|
84 |
THERAVANCE BIOPHARMA R&D IP, LLC et al v. EUGIA PHARMA SPECIALTIES LTD. et al |
1:23-cv-00926 |
D.N.J. |
|
|
|
|
85 |
Vertex Pharmaceuticals Incorporated v. Aurobindo Pharma Limited et al |
1:23-cv-00582 |
D.Del. |
|
|
|
|